Pneumococcal Vaccination in Older Adults An Update for Pharmacists

摘要

ABSTRACT: For nearly 50 years, vaccination of high-risk individuals has led to'a decrease in the incidence of invasive pneumococcal diseases, such as bacteremia and meningitis. However, for older adult populations, PPSV23 (Pneumovax-23) has not demonstrated ■ consistent protection against pneumococcal.pneumonia in clinical trials. Based on recent data from the'CAPITA trial showing both decreased episodes of community acquired pneumonia and a reduction of invasive pneumococcal disease, the CDC's Advisory Committee on Immunization Practices recently updated the vaccination schedule to include both PPSV23 and PCV13 (Prevnar 13) for those aged >65 years.